Navigating peptide stoichiometry requires absolute clarity regarding sequence purity, molecular mass, and counterion content. As a primary Bronchogen molar ratio supplier, PX1 Research provides institutional laboratories with fully characterized, research-grade compounds verified through lot-specific analytical documentation.
Navigating peptide stoichiometry requires absolute clarity regarding sequence purity, molecular mass, and counterion content. As a primary Bronchogen molar ratio supplier, PX1 Research provides institutional laboratories with fully characterized, research-grade compounds verified through lot-specific analytical documentation.
When evaluating a Bronchogen molar ratio supplier, researchers require precise molecular weight data, exact stoichiometric salt ratios, and verified analytical purity to calculate accurate molar concentrations ( micromolar or millimolar ) in preclinical assays. PX1 Research supplies USA-manufactured, research-grade Bronchogen accompanied by lot-specific mass spectrometry and RP-HPLC documentation for precise experimental design.
In cell culture assays and cell-free biochemical experiments, relying solely on total gross mass without adjusting for peptide purity or counterion presence introduces significant experimental error. A reliable supplier must provide comprehensive documentation detailing net peptide content, residual trifluoroacetate (TFA) or acetate content, and verified molecular weight to ensure precise molar ratio calculations across all experimental replicates.
Bronchogen is a synthetic short-chain peptide bioregulator studied primarily in respiratory cell culture models and tissue-specific gene expression research. Structurally classified as a tetrapeptide (Ala-Glu-Asp-Leu), its theoretical monoisotopic molecular weight is approximately 446.45 g/mol. However, when working with synthesized peptides, the gross mass measured on a laboratory scale does not equal the molar mass of the active peptide sequence alone.
During solid-phase peptide synthesis (SPPS), peptides are purified using mobile phases containing acid counterions. Consequently, the final lyophilized product exists as a peptide salt. To establish an accurate molar ratio in downstream assays, investigators must differentiate between gross lyophilized weight and effective peptide mass. For detailed specifications on theoretical mass versus analytical recovery, researchers can consult our comprehensive catalog of research peptides.
Understanding this molecular distinction is crucial for quantitative biochemical studies. If a protocol specifies a 10 micromolar working solution of Bronchogen, failing to account for counterion mass fraction results in systematically under-dosed cell cultures. PX1 Research addresses this challenge by delivering full sequence verification via electrospray ionization mass spectrometry (ESI-MS) on every lot, ensuring investigators have the exact molecular metrics required for precise stoichiometry.
To calculate the true molarity of a Bronchogen solution, investigators must utilize the net peptide content (NPC) percentage reported on the lot-specific Certificate of Analysis (COA). Net peptide content represents the actual proportion of amino acid polymer relative to total mass, excluding bound counterions and residual moisture. The baseline formula for calculating target molar concentrations is defined as:
Moles of Active Peptide = ( Gross Weight in Grams x Net Peptide Content Percentage ) / Molecular Weight (g/mol)
For example, if a laboratory reconstitutes 5 milligrams of lyophilized Bronchogen powder with a verified net peptide content of 84% and a molecular weight of 446.45 g/mol, the true active peptide mass is 4.2 milligrams (0.0042 g). Dividing this by 446.45 g/mol yields approximately 9.41 micromoles of peptide. Reconstituting this quantity in 9.41 milliliters of solvent yields an exact 1.0 millimolar stock solution. Understanding these parameters is part of standard protocols detailed in our guide on peptide solubility and reconstitution.
Without lot-specific net peptide content data, researchers risk variance up to 20% between experimental runs. As an institutional supplier, PX1 Research provides the quantitative metrics required to convert mass to moles with absolute precision, eliminating batch-to-batch operational variability.
In vitro data indicate that short synthetic bioregulators like Bronchogen modulate chromatin accessibility and gene expression patterns in pulmonary epithelial tissue models. Preclinical studies suggest that short peptide sequences enter cellular nuclei, interacting directly with specific histone proteins and DNA promoter regions to influence transcription rates of structural proteins.
In primary bronchial fibroblast cultures, researchers utilize controlled molar ratios of Bronchogen to investigate collagen synthesis pathways, inflammatory cytokine expression (such as IL-6 and TNF-alpha), and oxidative stress markers. Experimental designs typically evaluate dose-dependent responses across concentration gradients ranging from 1 nanomolar to 100 micromolar.
Furthermore, rodent models evaluating lung tissue homeostasis have explored the systemic and localized delivery of short peptide bioregulators. These preclinical assays aim to elucidate signaling cascades involved in tissue repair and alveolar remodeling. All materials supplied by PX1 Research are intended exclusively for such laboratory-based, in vitro, and animal research models; human administration is strictly prohibited.
Bronchogen belongs to a broader class of short synthetic peptide bioregulators engineered to evaluate tissue-specific gene expression. When designing comparative multi-peptide assays, researchers frequently examine Bronchogen alongside other tissue-targeted short peptides to assess specificity versus generalized regulatory mechanisms.
For instance, researchers studying endothelial and immune signal pathways often compare Bronchogen with Vilon, a synthetic dipeptide (Lys-Glu) investigated for its effects on chromatin structure in immune cells. Similarly, investigators evaluating systemic anti-aging and telomerase activity pathways frequently incorporate Epitalon alongside Bronchogen to differentiate between tissue-restricted pulmonary responses and systemic pineal-gland-derived regulatory cascades. Another common comparator in connective tissue and chondrocyte repair assays is Cartalax, a synthetic tripeptide (Ala-Glu-Asp) structurally related to Bronchogen but optimized for cartilage model systems. Reviewing the comparative stoichiometric properties across these compounds ensures balanced molar concentrations across multiplexed experimental arms.
Evaluating a Bronchogen molar ratio supplier requires rigorous scrutiny of their analytical validation procedures. High purity is essential for reliable quantitative data; impurities such as truncated sequences or deletion peptides can compete for cellular targets or alter measured molar concentrations.
PX1 Research subjects every production lot to dual analytical verification using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS). RP-HPLC establishes chromatographic purity, verifying that the primary peptide peak represents >= 98% of total integrated area. Mass spectrometry confirms the exact molecular weight, ensuring no incorrect sequence assembly occurred during synthesis. Researchers can review our methodology in detail through our analysis of mass spectrometry peptide verification.
Equally critical for cell culture applications is endotoxin control. Bacterial lipopolysaccharides (LPS) cause severe inflammatory responses in cell models, skewing experimental results. PX1 Research enforces stringent quality thresholds, verifying that all research peptides contain endotoxin levels below 0.01 EU/mg via Chromogenic LAL testing. Learn more about our purity protocols on our dedicated endotoxin testing reference page.
Proper reconstitution is required to preserve peptide stability and ensure consistent molar concentrations. Bronchogen is supplied as a sterile, lyophilized cake or powder. To prevent degradation, reconstitution protocols must adhere to strict aseptic techniques within a laminar flow hood.
Researchers typically utilize sterile bacteriostatic water, sterile 0.9% sodium chloride, or phosphate-buffered saline (PBS, pH 7.4) as primary solvents depending on downstream assay compatibility. When preparing high-concentration stock solutions, initial solubilization in a minimal volume of sterile water followed by buffer expansion is recommended if buffer salts induce salting-out effects.
Once reconstituted into liquid stock solutions, Bronchogen should be divided into single-use laboratory aliquots to avoid repeated freeze-thaw cycles. Freeze-thaw cycles cause mechanical shear stress and localized concentration gradients that induce peptide aggregation, altering effective molarity over time.
Lyophilized Bronchogen must be stored under controlled thermal conditions to maintain peptide bond integrity. For short-term laboratory holding (under 30 days), desiccated storage at -20°C is acceptable. For long-term preservation (up to 24 months), lyophilized vials should be kept at -80°C in a temperature-monitored freezer.
Vials should be allowed to equilibrate to ambient room temperature before opening the seal. Opening cold vials exposes the desiccated powder to atmospheric moisture, causing condensation that alters gross sample weight and hydrolyzes peptide bonds.
Reconstituted liquid aliquots stored at -20°C remain stable for short-term experimental series, but storage at -80°C is recommended for multi-month projects. Maintaining strict cold-chain management guarantees that calculated molar ratios remain consistent from the first assay replicate to the last.
PX1 Research serves as a trusted partner for academic, corporate, and independent research institutions across the United States. All PX1 compounds are manufactured domestically in cGMP-compliant facilities operating under strict ISO 9001 and ISO 17025 quality management frameworks.
Every batch of Bronchogen includes a publicly accessible, lot-specific Certificate of Analysis detailing RP-HPLC purity profiles, mass spectral identification, residual solvent screens, and quantitative endotoxin levels. This transparency enables researchers to calculate molar ratios with complete confidence.
To prevent project delays, PX1 Research maintains full inventory management with same-day dispatch on orders placed Monday through Friday from our centralized shipping centers in California and Arizona. Institutional procurement departments can coordinate bulk supply agreements and dedicated lot reservations directly through our wholesale lab portal.
What is the theoretical molecular weight of Bronchogen for molar ratio calculations?
The theoretical molecular weight of Bronchogen (tetrapeptide sequence Ala-Glu-Asp-Leu) is approximately 446.45 g/mol. When calculating exact molar concentrations, researchers must reference the lot-specific COA for net peptide content adjustments.
Why is net peptide content critical when determining Bronchogen molarity?
Net peptide content accounts for counterions (e.g., acetate or TFA) and residual moisture in lyophilized powders. Without adjusting for net peptide content, calculated molarities will overestimate actual peptide concentration by 10% to 20%.
How does PX1 Research verify Bronchogen purity?
PX1 Research verifies purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure >= 98% purity, alongside Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm sequence identity and molecular weight.
What endotoxin threshold does PX1 Research guarantee for Bronchogen?
PX1 Research guarantees that research-grade Bronchogen contains endotoxin levels below 0.01 EU/mg, confirmed via chromogenic LAL testing to prevent cellular toxicity in sensitive in vitro models.
What solvent is recommended for reconstituting Bronchogen for in vitro assays?
Sterile phosphate-buffered saline (PBS, pH 7.4), sterile 0.9% saline, or sterile water for injection are standard solvents. Solvent selection depends on the target buffer compatibility of the specific cell culture assay.
How should reconstituted Bronchogen stock solutions be stored?
Reconstituted stock solutions should be aliquoted into single-use volumes and stored at -20°C or -80°C. Repeated freeze-thaw cycles must be avoided to prevent peptide degradation and aggregation.
Where is PX1 Research Bronchogen manufactured and shipped from?
PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and dispatched directly from distribution hubs in California and Arizona with same-day shipping on business days.
Is Bronchogen supplied by PX1 Research approved for therapeutic human use?
No. Bronchogen supplied by PX1 Research is strictly for laboratory research, in vitro experiments, and preclinical animal models. It is not for human or veterinary use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.